---
title: "華潤醫藥完成發行 11 億元公司債券"
description: "智通財經 APP 訊，華潤醫藥公佈，本金總額人民幣 11 億元的第一期 2025 年公司債券已發行，期限三年，票面年利率為 1.82%。所得款項淨額將用於生產性支出，包括償還公司債務、補充營運資金、項目開發與營運支出、與科技創新相關的投資以及符合適用法律法規的其他用途。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262026444.md"
published_at: "2025-10-21T10:21:04.000Z"
---

# 華潤醫藥完成發行 11 億元公司債券

> 智通財經 APP 訊，華潤醫藥公佈，本金總額人民幣 11 億元的第一期 2025 年公司債券已發行，期限三年，票面年利率為 1.82%。所得款項淨額將用於生產性支出，包括償還公司債務、補充營運資金、項目開發與營運支出、與科技創新相關的投資以及符合適用法律法規的其他用途。

智通財經 APP 訊，華潤醫藥 (03320) 公佈，本金總額人民幣 11 億元的第一期 2025 年公司債券已發行，期限三年，票面年利率為 1.82%。所得款項淨額將用於生產性支出，包括償還公司債務、補充營運資金、項目開發與營運支出、與科技創新相關的投資以及符合適用法律法規的其他用途。

### Related Stocks

- [03320.HK - 華潤醫藥](https://longbridge.com/zh-HK/quote/03320.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| CICC Reaffirms Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) | In a report released yesterday, from CICC maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H, with a  | [Link](https://longbridge.com/zh-HK/news/276199846.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| Fitch Affirms Power Finance Corporation And REC Limited At 'Bbb-'/Stable On Merger Plan | Power Finance Corporation Ltd :FITCH: AFFIRMS POWER FINANCE CORPORATION AND REC LIMITED AT 'BBB-'/STABLE ON MERGER PLAN | [Link](https://longbridge.com/zh-HK/news/276130979.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-HK/news/276113491.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。